

# Lead selection of allergen non-binding hybrid immunoglobulin E for the treatment of allergic severe asthma

FatiAbGen Co., Ltd.



IMMUNOLOGY	Lead
Product Type	Allergen non-binding IgE/IgG hybrid immunoglobulin E
Indication	Allergic asthma (IgE-mediated allergic disease)
Target	FcεR1α (IgE receptor)
MoA(Mechanism of Action)	<ol style="list-style-type: none"> <li>1. Competing IgE for the binding to FcεR1α</li> <li>2. Disrupting IgE from FcεR1α-IgE complex</li> </ol>
Competitiveness	<ol style="list-style-type: none"> <li>1. Novel structure</li> <li>2. Target differentiation</li> <li>3. Superiority compared to competing drug, omalizumab</li> </ol>
Development Stage	Lead
Route of Administration	Subcutaneous injection